Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $306.1M | $385.2M | $455.9M | $106.9M | $126M | |
| Gross Profit | $255.7M | $325.3M | $382.8M | $91.4M | $105.7M | |
| Operating Income | $28M | $56.5M | $63.6M | $19.7M | $19.2M | |
| EBITDA | $38M | $66.9M | $74.3M | $22.3M | $21.9M | |
| Diluted EPS | -$0.32 | -$1.55 | $0.31 | -$0.99 | $0.08 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $271.3M | $262.5M | $369M | $494.9M | $659.4M | |
| Total Assets | $315.1M | $352.5M | $476.9M | $629.2M | $834.3M | |
| Current Liabilities | $403.7M | $189.8M | $226.8M | $272.9M | $316.9M | |
| Total Liabilities | $445.1M | $293M | $439M | $330.9M | $386.6M | |
| Total Equity | -$130M | $59.5M | $37.9M | $298.3M | $447.7M | |
| Total Debt | -- | -- | $7.3M | $7.8M | $17.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $94M | $110M | $152.7M | $41.7M | $33.3M | |
| Cash From Investing | -$63.1M | -$130.4M | -$38.1M | -$18.7M | $63.8M | |
| Cash From Financing | $19.2M | $18.5M | $29.4M | $5.5M | $5.3M | |
| Free Cash Flow | $87.8M | $98.8M | $139.1M | $39.8M | $30M | |
Cellebrite DI Ltd. engages in the provision of digital investigative solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Its services include training and advisory, value realization, advanced services, and technical customer support. The firm also offers software solutions and analytic tools designed to accelerate digital investigations and address the growing complexity of handling crime and security challenges in the digital era. The company was founded on April 13, 1999 and is headquartered in Petach Tikva, Israel.
In the current month, CLBT has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CLBT average analyst price target in the past 3 months is $24.71.
According to analysts, the consensus estimate is that Cellebrite DI Ltd. share price will rise to $24.71 per share over the next 12 months.
Analysts are divided on their view about Cellebrite DI Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cellebrite DI Ltd. is a Sell and believe this share price will drop from its current level to $23.00.
The price target for Cellebrite DI Ltd. over the next 1-year time period is forecast to be $24.71 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
According to Wall Street analysts, the consensus rating for Cellebrite DI Ltd. is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
You can purchase shares of Cellebrite DI Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cellebrite DI Ltd. shares.
Cellebrite DI Ltd. was last trading at $18.41 per share. This represents the most recent stock quote for Cellebrite DI Ltd.. Yesterday, Cellebrite DI Ltd. closed at $18.06 per share.
In order to purchase Cellebrite DI Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $3.9T
P/E Ratio: 36x
Market Cap: $3.8T
P/E Ratio: 39x
Regencell Bioscience Holdings Ltd. [RGC] is up 22.74% over the past day.
Innodata, Inc. [INOD] is up 4.84% over the past day.
AeroVironment, Inc. [AVAV] is up 6.62% over the past day.